FcγR requirements and costimulatory capacity of Urelumab, Utomilumab, and Varlilumab
IntroductionTargeting costimulatory receptors of the tumor necrosis factor receptor (TNFR) superfamily with agonistic antibodies is a promising approach in cancer immuno therapy. It is known that their efficacy strongly depends on FcγR cross-linking.MethodsIn this study, we made use of a Jurkat-base...
Gardado en:
| Principais autores: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Frontiers Media S.A.
2023-07-01
|
| Series: | Frontiers in Immunology |
| Assuntos: | |
| Acceso en liña: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1208631/full |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|